SHPH Shuttle Pharma Total Debt to Capital

SHPH (Shuttle Pharmaceuticals Holdings) - company brandmark

The historical debt-to-equity chart for Shuttle Pharmaceuticals (SHPH) is 0.01. The company's operations focus on developing agents in US laboratories that increase the radiosensitivity of head and neck neoplasms. Scaling prospects depend on integrating patented methods into global oncology practice, while the current stage is characterized by the expenditure of available funds on intensive scientific research.

Debt to Equity Ratio: shuttlepharma.com (SHPH) for 04/28/2023 - 10/28/2026

Comprehensive metric breakdowns and analytics for Shuttle Pharmaceuticals Inc (SHPH)

- price and consensus price forecast:
Stock Price Shuttle Pharmaceuticals Holdings|SHPH - Consensus Target
- market capitalization data:
Market Capitalization Shuttle Pharmaceuticals|SHPH - Enterprise Value
- book capitalization data:
Net Assets per Single Share Shuttle Pharmaceuticals|SHPH - Accounting Capitalization|Market Capitalization to Book Value Ratio shuttlepharma.com|SHPH - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Shuttle Pharmaceuticals|SHPH - Long-Term Liabilities to Capital|Short-Term Debt to Equity Shuttle Pharmaceuticals|SHPH - Aggregate Debt Obligations|Debt to Book Value Shuttle Pharmaceuticals|SHPH - Company Long-Term Loans and Borrowings|Company Short-Term Debts Shuttle Pharmaceuticals
Comprehensive company analysis:SHPH - Shuttle Pharmaceuticals Holdings
Product sample of Shuttle Pharmaceuticals

This ratio determines the degree of financial leverage by comparing total liabilities to net assets to assess insolvency risks and capital structure efficiency. By analyzing the dynamics of equity dependence on debt via GURU.Markets, an investor can observe the balance of borrowed funds, which is critically important for Shuttle Pharmaceuticals (SHPH) during the development of innovative sensitizers for oncology.

Main competitors

Total Debt to Capital CNSP